Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Progressive multiple sclerosis

ABSTRACT: Progressive multiple sclerosis

PROVIDER: PRJNA966951 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24422100.fastq.gz	Fastqsanger.gz
	SRR24422101.fastq.gz	Fastqsanger.gz
	SRR24422036_1.fastq.gz	Fastqsanger.gz
	SRR24422036_2.fastq.gz	Fastqsanger.gz
	SRR24422037_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 84

Similar Datasets

Mapping the Molecular Signature of Progressive Multiple Sclerosis [194017]

Project description:Multiple Sclerosis is a complex neurological disorder characterised by inflammation, demyelination, and neurodegeneration of the central nervous system. While treatments exist for relapsing-remitting multiple sclerosis, therapeutic options for the progressive forms remain limited, highlighting the need to understand their distinct pathological mechanisms. To identify subtype specific molecular signatures in patients with multiple sclerosis, bulk RNA sequencing was performed in 90 brain tissue samples from donors with relapsing-remitting, secondary progressive, and primary progressive multiple sclerosis, as well as controls without the disease. This study provides open access to transcriptomic data from multiple sclerosis tissue samples, enabling other researchers to perform independent analyses, validate findings, and generate new hypotheses.

2025-02-26 | GSE290450 | GEO

Mapping the Molecular Signature of Progressive Multiple Sclerosis [197191]

2025-02-26 | GSE290552 | GEO

Mapping the Molecular Signature of Progressive Multiple Sclerosis

Project description:Mapping the Molecular Signature of Progressive Multiple Sclerosis

| PRJNA1228601 | ENA

Identification of early neurodegenerative pathways in progressive multiple sclerosis

Project description:Identification of early neurodegenerative pathways in progressive multiple sclerosis

| PRJNA730884 | ENA

Mapping the Molecular Signature of Progressive Multiple Sclerosis [197191]

Project description:Mapping the Molecular Signature of Progressive Multiple Sclerosis [197191]

| PRJNA1228611 | ENA

Mapping the Molecular Signature of Progressive Multiple Sclerosis [194017]

Project description:Mapping the Molecular Signature of Progressive Multiple Sclerosis [194017]

| PRJNA1228055 | ENA

Novel Biomarkers and Interferon Signature in Secondary Progressive Multiple Sclerosis

Project description:Novel Biomarkers and Interferon Signature in Secondary Progressive Multiple Sclerosis

| PRJNA1036589 | ENA

Proteomic profiling of progressive multiple sclerosis brains and neural cell types

Project description:Label-free global proteomic analysis of progressive multiple sclerosis (P-MS) and control (ODC) brain tissue (cortex/CTX, normal appearing white matter/NAWM, white matter lesions/WML), primary human neural cell types (neurons, microglia, astrocytes, oligodendrocyte progenitor cells), and CNS tissue (brain, spinal cord) from mouse models of MS (EAE and cuprizone).

2025-01-07 | MSV000096790 | MassIVE

Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis

Project description:Interferon (IFN) beta-1a is an approved treatment for relapsing remitting multiple sclerosis (RRMS) and has been examined for use in secondary progressive multiple sclerosis (SPMS). However, no information regarding blood transcriptional changes induced by IFN treatment in SPMS patients is available. Our aim was to identify a subgroup of SPMS patients presenting a gene expression signature similar to that of RRMS patients who are clinical responders to IFN treatment.

2015-10-06 | GSE73608 | GEO

Siponimod selectively enriched regulatory T and B lymphocytes in active secondary progressive multiple sclerosis patients

Project description:Siponimod selectively enriched regulatory T and B lymphocytes in active secondary progressive multiple sclerosis patients: 20 SPMS baseline including 3 repeats, 19 treated with 5 placebo and 14 siponimod treated.

2020-04-07 | GSE141381 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data